| Type | Title | Date Released | |
|---|---|---|---|
8-K | ImmuCell Announces a 46% Increase in Product Sales in Quarter Three of 2026 | ||
10-Q | Form 10-Q | ||
8-K | ImmuCell Reports Second Quarter 2026 Financial Results and Capacity Expansion Plans | ||
8-K | ImmuCell Reports Preliminary Q2 2026 Sales Growth of 11.5% and Six-Month Growth of 20.9% | ||
4 | te Boekhorst Paul Francis Olivier (Reporting) | ||
8-K | ImmuCell Corporation Announces Results of 2026 Annual Meeting of Stockholders | ||
8-K | ImmuCell Corporation Authorizes Manufacturing Capacity Expansion for First Defense® Product Line | ||
8-K | ImmuCell Reports Strong First Quarter 2026 Financial Results | ||
10-Q | Form 10-Q | ||
10-K/A | Form 10-K/A | ||
8-K | ImmuCell Corporation Enters Settlement Agreement with Norbrook Laboratories Limited | ||
DEF 14A | Form DEF 14A |